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The prevention of subclinical ketosis (SCK) is based on maintaining adequate nutrition in 
dairy cows during the dry period and close to calving. Recently, an oral-route monensin 
bolus to prevent SCK was approved in Europe. The present study aims to define the 
allocation of resources for SCK management at the herd level and evaluate the profitability 
of administering monensin boluses in cows at risk for SCK. A stochastic model was used 
to calculate the total cost of SCK for a population with a given prevalence of cows at risk 
for SCK. This model included the ability of the farmer to correctly target and preventatively 
treat these cows at risk for SCK. The results clearly demonstrated economic synergy 
between two management practices. First, reducing the prevalence of cows at risk for 
SCK dramatically reduces the total cost of SCK and seems profitable in most situations. 
Second, monensin bolus use to reduce the occurrence of SCK in cows already at risk for 
SCK is cost-effective. The results also highlighted three economic strategies to manage 
SCK in the dairy industry in Europe. First, monensin bolus use throughout an entire herd 
when the prevalence of cows at risk for SCK is high is only profitable in the short-term as 
a tool to correct acute deterioration at the herd level. Second, decreasing the prevalence 
of cows at risk for SCK through adequate feeding in the dry period is of financial interest 
as a baseline strategy when prevalence is high, assuming moderate additional cost 
linked to the new diet. Third, monensin bolus use when the prevalence of cows at risk for 
SCK is low is also profitable as a long-term strategy when only cows at high risk for SCK 
(such as cows that are over-conditioned, old, or have a previous history of SCK-related 
disorders) are targeted for preventative treatment. Authors suggest to use the present 
results considering that farmers have a correct, but not perfect, ability to target animals 
to be preventively targeted with the monensin bolus. Further work is required to facilitate 
the early identification of cows at risk for SCK.
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inTrODUcTiOn
Subclinical ketosis (SCK) is a common metabolic disorder in 
dairy cows caused by a strong dietary negative energy balance 
around or after calving. A certain degree of negative energy 
balance is expected in cows during late gestation and early 
lactation; however, SCK occurs if the blood ketone concen-
tration increases dramatically (1). The beta-hydroxybutyrate 
(BHBA) threshold for SCK diagnosis is generally between 1.2 
and 1.4  mmol/l (2). Increased concentrations of both BHBA 
and non-esterified fatty acids are markers of SCK. As a result of 
the imbalance between energy expenditure and ingestion, SCK 
is not only observed in high-producing dairy cows but also in 
cows with moderate milk production and inadequate ingestion 
or feeding around calving. The lactational prevalence of SCK in 
Europe is estimated to be between 25 and 47% (3,  4) and up 
to 85% of herds are reported to have an intra-herd prevalence 
of more than 25% (5).
Subclinical ketosis has both societal and economic implica-
tions. First, SCK is associated with an increased risk for the 
majority of health disorders (puerperal metritis, purulent 
vaginal discharge, placental retention, abomasum displace-
ment, mastitis, and lameness) observed in dairy cows during 
the early postpartum period (2). Consequently, SCK leads to 
increased antimicrobial use. The application of antimicrobials 
in herds with a low prevalence of SCK compared with herds 
with a moderate prevalence of SCK is, on average, 10 or 25% 
less frequent, depending on circumstances (6). SCK has a large 
impact on farm profitability. The total average cost of SCK 
in Europe was recently estimated to be €257 (i.e., US $283) 
per cow with SCK (95% prediction interval =  €74–442; US 
$81–487) (7). Decreased milk production during SCK only 
accounts for 11% of the total cost. Early culling and abomasum 
displacement are the two major contributors of SCK total 
cost. Furthermore, SCK total cost sensitivity to the feed cost 
margin  is low.
Subclinical ketosis prevention is based on maintaining 
adequate nutrition in dairy cows during the dry period. 
The most important risk factor during this period is over-
conditioned cows, which leads to fat cows at calving and 
reduced dietary intake around calving and during the early 
postpartum period (1, 8). Well-known methods to prevent 
SCK include adequate feeding of dry cows including adequate 
energy density diets, adequate management of early lactation 
diets, with for instance improved ingestion through adequate 
comfort of animals. Despite this, many cows remain at risk 
for SCK during the few weeks prior to calving. It is sometimes 
difficult to offer adequate diets to certain cows, such as those 
grazing in pastures. In particular, small farms face difficul-
ties in preparing an appropriate diet for low numbers of dry 
cows, often just one or two cows during the transition period. 
Regardless of the cause, the prevention of SCK is primarily 
based on a cow’s prepartum diet. Until recently in Europe, 
there was no preventative solution for cows that were fat at 
several weeks prepartum, and weight reduction at this stage 
increases the risk of developing SCK. Recently, an oral-route 
monensin bolus was authorized in Europe to prevent SCK 
when administered 3 weeks prior to calving in cows at risk for 
SCK. This drug has been intensively used outside of Europe 
(9, 10). In Europe, monensin is labeled for use in prepartum 
cows that are at risk for SCK, which are defined as cows that 
are over-conditioned, old, and have a history of SCK-related 
disorders during previous lactations1.
Therefore, the aim of the present study was to define (i) 
resources to be allocated for SCK management at the herd level 
without monensin bolus use and (ii) the profitability of monensin 
bolus use in cows at risk for SCK. Using economic modeling, this 
study sought to define optimal situations in terms of SCK-related 
herd management.
MaTerials anD MeThODs
concept and Model
A conceptual model aims to simulate a given population 
and various decisions resulting in different possibilities; such 
a model is calculated in five successive steps (Figure  1). A 
similar model was applied previously to assess antimicrobials 
(6). Briefly, the population included (i) a subpopulation of cows 
at risk for SCK at a prevalence (r), designated the SCK risk 
prevalence and (ii) a subpopulation of cows not at risk for SCK 
at a prevalence (1−r) (Step 1). Additionally, farmers may utilize 
a preventative treatment (monensin bolus) on cows at risk for 
SCK with the probability (p) (Step 2). Because farmers do not 
make perfect decisions, they may also treat a cow not at risk 
for SCK with a risk (q). A scenario lacking any preventative 
monensin bolus treatment was accounted for within the model 
with p =  q =  0 (Figure  1). Then, the following denotations 
were made:
  rp: the prevalence of cows at risk for SCK and preventatively 
treated.
  r(1 − p): the prevalence of cows at risk for SCK and not pre-
ventatively treated.
  (1 − r)q: the prevalence of cows not at risk for SCK and pre-
ventatively treated.
  (1 − r)(1 − q): the prevalence of cows not at risk for SCK and 
not preventatively treated.
The following step (Step 3) focused on the risk of a cow actu-
ally developing SCK (Figure 1). The following denotations were 
used: a, the risk of SCK for a cow at risk of SCK but preventatively 
treated; b, the risk of SCK for a cow at risk of SCK and not pre-
ventatively treated; c, the risk of SCK for a cow not at risk of SCK 
but preventatively treated; d, the risk of SCK for a cow not at risk 
of SCK and not preventatively treated.
The parameters b and d are related by Eq. 1.
 b = ×d RRSCK IF AT RISK  (1)
where RRSCK IF AT RISK is the relative risk of having SCK if risk factors 
are present in a given cow.
The parameters a and b are related by Eq. 2.
1 http://www.med-vet.fr/
FigUre 1 | conceptual flowchart. Flowchart representing a conceptual population for which various possible decisions are made. r is the prevalence of cows at 
risk for subclinical ketosis (SCK); p, q, a, b c, and d are event probabilities; T+ and T− represent a cow that does or does not receive preventative monensin bolus 
treatment, respectively; and K+ and K− represent a cow with or without SCK, respectively.
3
Raboisson and Barbier Profitability of Preventing SCK
Frontiers in Veterinary Science | www.frontiersin.org March 2017 | Volume 4 | Article 35
 a b= −×( )1 EFFMONENSIN  (2)
where EFFMONENSIN is the reduction in the prevalence of SCK due 
to monensin bolus use when administered to cows at risk for SCK.
The parameters d and a are related by Eq.  3 through Eqs  1 
and 2.
 a d= −× ×( )RR 1 EFFSCK IF AT RISK MONENSIN  (3)
The parameter c was defined as d, meaning that the bolus has 
no efficacy on cows not at risk for SCK. The parameter d (risk of 
SCK for a cow not at risk for SCK and not preventatively treated 
with monensin) represents the baseline “natural” risk of SCK in 
cows not exposed to risk factors. The overall prevalence of SCK 
(PSCK) and the number of preventative treatments (NTRT) in the 
studied population were defined using Eqs 4 and 5 (Step 4).
 P rpa r p b r qc r q dSCK 1 1 1 1= + − + − + − −( ) ( ) ( )( )  (4)
 N rp r qTRT 1= + −( )  (5)
A targeting index (TI) was then defined according to Eq. 6, 
which represents the ability of the decision maker to only treat 
cows at risk.
 TI 1= + −rp r q( )  (6)
The outcome variable of the model was the total cost associated 
with SCK management (TotalCostSCK) at the herd level (Eq. 7).
TotalCost Cost CostSCK TRT SCK TRT TRT SCK SCK= + = +N C P C× ×  (7)
where CostTRT: the total cost of the monensin boluses for a given 
herd and situation; CostSCK: the total cost of SCK for a given herd 
(linked to choices made); CTRT: the price of one monensin bolus; 
and CSCK: the price of one case of SCK.
The model was run using Scilab open source software2 with 
10,000 iterations, and 95% prediction intervals (PIs) and 95% 
confidence intervals (CIs) were calculated. PIs facilitate the 
prediction of the situation for the next farm with 95% probability 
and CIs indicate the situation in 95 of 100 farms visited.
calibration
The key input parameters of the models are summarized in 
Table 1. The majority of the input parameters were included as 
a law of distribution (normal or log-normal) and not as a point 
estimate. The value of the parameter d was calculated according 
to previously defined methods (6): the obtained value of d was 
approximately 15% in the majority of cases and 10% in rare 
2 http://www.scilab.org.
FigUre 2 | The total cost of subclinical ketosis (scK) management (TotalcostscK) for different targeting index (Ti) values and three hypothetical 
prevalences of cows at risk for scK (r) when rrscK iF aT risK = 2. RRSCK IF AT RISK is the relative risk of having SCK if risk factors are present in a given cow; p is the 
proportion of cows at risk for SCK that are preventatively treated with monensin; and q is the proportion of cows not at risk for SCK that are preventatively treated 
with monensin. The graph is read as follows: for a given risk prevalence (for example, r = 50%), going from a situation without any preventative treatment (point A) to 
perfectly targeted preventative treatment (point B) is profitable because it is associated with a decrease in the total cost; without any preventative treatment, the total 
cost of the disease decreases as the SCK risk prevalence r decreases (for example, from r = 50 to 20%, meaning from point A to point C).
TaBle 1 | input parameters for the model.
law Main scenario sensitivity  
analysis
reference
d N 0.15 (0.04)a 0.10 (0.03)a Raboisson 
et al. (6)
RRSCK IF AT RISK LN 0.76 (0.60)b or 
1.50 (0.62)b
Raboisson 
et al. (6)
EFFMONENSIN // 0.66 0.45 and 0.85 Raboisson 
et al. (6)
CSCK, € per cow LN 257 (94) 177 (82)  
and 434 (123)
Raboisson 
et al. (7)
CTRT, € per bolus LN 36 (3)
LN, log-normal; N, normal.
aMean (and SD).
bCorresponding to RRSCK IF AT RISK = 2.0 and 4.5.
d is the risk of subclinical ketosis (SCK) for a cow not at risk for SCK and not 
preventatively treated; RRSCK IF AT RISK is the relative risk of having SCK if risk factors are 
present in a given cow; EFFMONENSIN is the reduction in the prevalence of SCK due to 
monensin bolus use when administered to cows at risk for SCK; CSCK is the price of 
one case of SCK; and CTRT is the price of one monensin bolus.
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situations (Table  1). RRSCK IF AT RISK was defined according to a 
meta-analysis (11) conducted on the outcomes “parity” and 
“body condition score” (BCS). The literature including methods, 
results, and discussion of the meta-analysis are presented in Text 
S1 and Table S1 in Supplementary Material. The results of the 
meta-analysis suggested difficulties in precisely defining RRSCK IF 
AT RISK. Two scenarios were then proposed, in which RRSCK IF AT RISK 
was defined through LN (0.76, 0.60) or LN (1.50, 0.62) (Table 1). 
EFFMONENSIN was evaluated according to previously defined 
methods (6), based on a report on monensin bolus use by the 
Committee for Medicinal Products for Veterinary Use from the 
European Medicines Agency3 and from four other studies (9, 10, 
12, 13). Three values of EFFMONENSIN (Table S2 in Supplementary 
Material) were retained (Table 1). CSCk was previously defined (7). 
The most plausible, but also the maximal and minimal estima-
tions, were retained from CSCk. All models were run for an average 
100-head dairy cow herd.
resUlTs
The TotalCostSCK was first reported for various TI and three values 
of r (Figures 2 and 3). Each cross represents one combination of p 
and q values (increment of 0.1 unit). As expected, the TotalCostSCk 
decreased when r decreased in the absence of any preventative 
treatment (stars in Figures 2 and 3). In other words, reducing 
the value of r by modifying herd management decreased the 
TotalCostSCK [for example, point A (r = 50%) to B (r = 20%)], 
particularly when the value of RRSCK IF AT RISK was high (Figure 3 
compared with Figure 2). The change in the TotalCostSCk when r 
decreased represented the expected reduction in losses, i.e., saved 
losses, but did not include the extra costs associated with changes 
in herd management to achieve the new (lower) value of r. For a 
given value of r, the prevention of SCK with monensin bolus use 
was profitable (for example, point A to C for r = 50%) provided 
3 http://www.ema.europa.eu.
FigUre 3 | The total cost of subclinical ketosis (scK) management (TotalcostscK) for different targeting index (Ti) values and three different 
prevalences of cows at risk for scK (r) when rrscK iF aT risK = 4.5. RRSCK IF AT RISK is the relative risk of having SCK if risk factors are present in a given cow; p is 
the proportion of cows at risk for SCK that have been preventatively treated with monensin; and q is the proportion of cows not at risk for SCK that have been 
preventatively treated with monensin. The graph is read as follows: for a given risk prevalence (for example, r = 50%), going from a situation without any 
preventative treatment (point A) to perfectly targeted preventative treatment (point B) is profitable because it is associated with a decrease in the total cost; 
without any preventative treatment, the total cost of the disease decreases as the risk prevalence r decreases (for example, from r = 50 to 20%, meaning from 
point A to point C).
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that the TI increased, indicating that the farmer treated only cows 
at risk for SCK. In cases where it was difficult for the farmer to 
administer monensin boluses only to cows at risk for SCK (i.e., 
the TI decreased), monensin bolus use increased the TotalCostSCk 
compared with no bolus treatment. Therefore, it was not profit-
able. The change in the TotalCostSCK allowed by monensin bolus 
administration represented the expected earnings because the 
TotalCostSCK already included the prevention costs (i.e., the cost 
of the boluses). Monensin bolus use to prevent SCK decreased 
the TotalCostSCK to the extent that the TI increased regardless of 
the value of r. For example, up to €1,000 per herd was expected 
for r =  20%, RRSCK IF AT RISK =  4.5, and perfect monensin bolus 
use (TI =  1) compared with no preventative monensin bolus 
treatment. The financial situation of the farm was all the more 
improved by monensin bolus use than the TI was good and the 
value of r was high.
The TotalCostSCK was then reported for different values of r 
and for no monensin bolus use, a perfect TI or a good TI (less 
than a 20% error rate in targeting). Since targeting cows at risk for 
SCK is difficult and farmers are unlikely to make perfect decisions 
when targeting cows, a good TI (20% error rate for p and q) was 
considered in addition to a perfect TI. In the main scenario, with-
out any preventative medical treatment (p = q = 0), the average 
PSCK decreased from 33.8 to 17.2% (ORSCK IF AT RISK = 2) and from 
67.9 to 21.7% (ORSCK IF AT RISK = 4.5) when r decreased from 0.8 
to 0.1 (Figure 4). Perfect monensin bolus use (TI = 1, or p = 1, 
q = 0) or correct use (p = 0.8 and q = 0.2) led to the stabilization 
of PSCK to approximately the financial situation observed for the 
low value of r. Additionally, PSCK decreased slightly for a perfect 
TI and a RRSCK IF AT RISK = 2. The TotalCostSCK was always lower 
for a perfect TI compared with no preventative treatment or a 
good TI, as indicated in Figures 5–7. The break-even point was 
defined as the value of r below which a routine (perfect TI or good 
TI) was associated with a lower TotalCostSCK compared with the 
lack of preventative treatment; this is the value of r where the two 
lines cross on the graphs. The values of the break-even points 
were always near zero for the perfect TI (Table 2). This clearly 
demonstrates the profitability of monensin bolus use, regardless 
of the SCK risk prevalence and provided that targeting of the cows 
by the farmer was perfect. The profitability of monensin bolus 
use remained high in the majority of situations with a good TI. 
Monensin bolus use was not profitable in cases with a good TI and 
a low value of r, as demonstrated by the high break-even points 
(Table 2), all the more than EFFMONENSIN was low (Figure 6), CSCK 
was low (Figure 7) and the RRSCK IF AT RISK = 2.
As expected, the herd-level profitability of monensin bolus use 
was particularly important when the value of r was high, as dem-
onstrated by the gap between the lines on the graphs. Optimal 
economic situations, as defined as the lowest TotalCostSCK, were 
observed for the lowest values of r, independent of monensin 
bolus use. When the efficacy of monensin bolus use on cows not 
at risk for SCK was limited (i.e., c ≠ d), the TotalCostSCK did not 
change substantially (data not shown), and the TotalCostSCK and 
the break-even points were slightly decreased (Table 2). When 
FigUre 4 | The prevalence of subclinical ketosis (scK) for different simulations. RRSCK IF AT RISK is the relative risk of having SCK if risk factors are present in a 
given cow; r is the prevalence of cows at risk for SCK; targeting index (TI) is the targeting index; p is the proportion of cows at risk for SCK that have been 
preventatively treated with monensin; and q is the proportion of cows not at risk for SCK that have been preventatively treated with monensin. The mean values are 
presented for the main scenario for two values of RRSCK IF AT RISK and three situations involving monensin use: no use, good TI (20% error rate in targeting cows), and 
perfect TI (no error in targeting cows). The 95% (bottom left) and 80% (bottom right) PIs are represented for RRSCK IF AT RISK = 2.
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the value of d was fixed at N(0.10, 0.03) (Figure 5, bottom) instead 
of N(0.15, 0.04) (Figure 5, top), the results were unchanged, but 
the ranges of variation for the TotalCostSCK were reduced, and the 
values of the break-even points were higher than the values when 
RRSCK IF AT RISK =  2. The 95% CI ranges for all results were very 
narrow, indicating the results were precise. The 95 and 80% PI 
ranges indicated it was difficult to predict the expected changes in 
the TotalCostSCK for the next population of 100 heads (Figure 8). 
However, the expected prevalence of SCK was predicted with 
moderate precision (Figure 4).
DiscUssiOn
Decreasing the Prevalence of cows at 
risk for scK and Monensin Bolus Use are 
Both Profitable and synergic strategies
The present work analyzed the profitability of various scenarios 
regarding the management of SCK in the field. These options 
should be seen as a mix of the decisions made by a farmer or 
farm advisers and of the present situation in a herd. The results 
clearly showed synergy between a reduction in the prevalence 
of cows at risk for SCK (value of r) and monensin bolus use to 
reduce the occurrence of SCK in cows already at risk for SCK. 
Four situations may be considered.
First, if the farmer has a high number of cows at risk for SCK 
during the mid-dry period, monensin bolus use is profitable 
and significantly reduces the economic impact due to SCK. 
This conclusion remained valid irrespective of the calibration 
retained. The economic relevance of this strategy (monensin 
bolus use) is in accordance with the constraints observed in 
the field because there is no other satisfactory solution at this 
stage to manage the problem in these cows. The profitability of 
monensin bolus use was demonstrated for high or low values of 
r; however, the stakes are different between these two situations. 
Monensin bolus use when the prevalence of cows within a herd 
at risk for SCK is high is only financially justified as a short-term 
strategy since the economic optimum is not reached. Therefore, 
reducing the value of the SCK risk prevalence (r) is of economic 
interest.
Second, reducing the value of the SCK risk prevalence 
(r) is associated with a decrease in the TotalCostSCK. This 
was expected since the cost associated with changes in the 
management of a dairy herd to achieve a low value of r was 
FigUre 5 | The total cost of subclinical ketosis (scK) management (TotalcostscK) for different simulations. RRSCK IF AT RISK is the relative risk of having SCK 
if risk factors are present in a given cow; r is the prevalence of cows at risk for SCK; TI is the targeting index; p is the proportion of cows at risk for SCK that have 
been preventatively treated with monensin; and q is the proportion of cows not at risk for SCK that have been preventatively treated with monensin. The mean 
values are presented for the main scenario for two values of RRSCK IF AT RISK, d = N(0.15, 0.04) (top) or d = N(0.10, 0.03) (bottom), and three situations involving 
monensin use: no use, good TI (20% error rate in targeting cows), and perfect TI (no error in targeting cows).
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not included in the TotalCostSCK. A decrease in the TotalCostSCK 
due to a decrease in the SCK risk prevalence (r) should be 
compared with the expected costs associated with changes in 
diet or management before making any decisions. However, 
these costs are difficult to estimate. Profitability of the decrease 
in the value of SCK risk prevalence (r) is only observed when 
the cost of diet improvement is low, which is expected since the 
dietary requirements of dry cows are simple, and imbalance is 
often a result of excess diet and not diet deficiency. Comparison 
between the expected saved losses due to the reduction in SCK 
risk prevalence (r) and the expected extra costs necessary to 
improve the diets of dry cows suggests that this strategy is 
profitable in the majority of herds. This statement has yet to 
be verified by the end-users of the present results before any 
decision to be made in a farm.
Third, based on the break-even points, monensin bolus use 
was minimally profitable in herds with a low SCK risk prevalence. 
The break-even points, which indicate the value of SCK risk 
prevalence below which it is profitable to use monensin boluses, 
were often low for good TI and were nearly equal to zero for 
perfect TI. Taken together, these results suggest that monensin 
bolus use is a good strategy for low SCK risk prevalences, but 
the success of this strategy depends on the ability of the farmer 
to only treat the cows at risk for SCK. The expected saved losses 
will remain limited.
Fourth, further reductions in the SCK risk prevalence (r) 
in herds that already have a low risk prevalence are technically 
difficult or impossible to achieve. Such reductions may even 
worsen the situation, such as in cases of inappropriate changes 
in the diet of dry cows, which would create new risks for SCK in 
dry cows that were not initially at risk for SCK. The definition 
of the prevalence of cows at risk for SCK or the cows with SCK 
corresponding to the economic optimum is out of the scope of 
the present work.
In summary, the present work showed that (i) monensin 
bolus use is profitable in the short-term only is high (herd-
level acute situation) when the SCK risk prevalence (r) is high, 
(ii) decreasing the SCK risk prevalence r (up to a value to be 
determined by further research) is a baseline strategy when 
this SCK risk prevalence is high, and (iii) monensin bolus use 
when the SCK risk prevalence (r) is low is a profitable long-term 
strategy only if the cows are targeted precisely based on their 
8Raboisson and Barbier Profitability of Preventing SCK
Frontiers in Veterinary Science | www.frontiersin.org March 2017 | Volume 4 | Article 35
FigUre 6 | The total cost of subclinical ketosis (scK) management (TotalcostscK) for different simulations in which eFFMOnensin changes. EFFMONENSIN is 
the reduction in the prevalence of SCK due to monensin bolus use when administered to cows at risk for SCK; r is the prevalence of cows at risk for SCK; TI is the 
targeting index; p is the proportion of cows at risk for SCK that have been preventatively treated with monensin; and q is the proportion of cows not at risk for SCK 
that have been preventatively treated with monensin. The mean values are presented for the main scenario in which RRSCK IF AT RISK = 2 (top) and three situations 
involving monensin use: no use, good TI (20% error rate in targeting cows), and perfect TI (no error in targeting cows).
FigUre 7 | The total cost of subclinical ketosis (scK) management (TotalcostscK) for different simulations when the unit total cost of scK (CscK) 
changes. r is the prevalence of cows at risk for SCK; TI is the targeting index; p is the proportion of cows at risk for SCK that have been preventatively treated with 
monensin; and q is the proportion of cows not at risk for SCK that have been preventatively treated with monensin. The mean values are presented for the main 
scenario in which RRSCK IF AT RISK = 2 (top) or 4.5 (bottom) and three situations involving monensin use: no use, good TI (20% error rate in targeting cows), and perfect 
TI (no error in targeting cows).
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TaBle 2 | Break-even points compared with no preventative treatment 
with monensin.
Break-even point (value of r)
rrscK iF aT risK = 2 rrscK iF aT risK = 4.5
c d eFFMOnensin CscK good  
Ti
Perfect 
Ti
good  
Ti
Perfect 
Ti
=d 0.1 0.45 257 0.51 0.02 0.14 0.00
=d 0.1 0.66 257 0.24 0.00 0.08 0.00
=d 0.1 0.85 257 0.16 0.00 0.06 0.00
=d 0.1 0.66 177 0.50 0.02 0.13 0.00
=d 0.1 0.66 434 0.11 0.00 0.05 0.00
≠da 0.1 0.66 257 0.17 0.00 0.00 0.00
d 0.15 0.66 257 0.55 0.02 0.12 0.00
ac = d(1 − EFFMONENSIN/2), i.e., the ability of monensin bolus use to limit the 
occurrence of SCK fixed at half for cows not at risk for SCK compared with cows at 
risk for SCK; the break-even points represent the value of r below which the strategy 
involving no preventative treatment was the most profitable; r is the prevalence of 
cows at risk for SCK; RRSCK IF AT RISK is the relative risk of having SCK if risk factors are 
present in a given cow; EFFMONENSIN is the reduction in the prevalence of SCK due to 
monensin bolus use when administered to cows at risk for SCK; CSCK is the price of 
one case of SCK; and targeting index (TI) measures whether the farmer treats only 
the cows at risk for SCK.
FigUre 8 | The total cost of subclinical ketosis (scK) management (TotalcostscK) for different simulations when rrscK iF aT risK = 2. r is the prevalence of 
cows at risk for SCK; TI is the targeting index; p is the proportion of cows at risk for SCK that have been preventatively treated with monensin; and q is the 
proportion of cows not at risk for SCK that have been preventatively treated with monensin. The mean values and their 95% (left) and 80% (right) PIs are presented 
for the main scenario and three situations involving monensin use: no use, good TI (20% error rate in targeting cows), and perfect TI (no error in targeting cows).
risk for SCK (by the farmer or other personnel). Further work 
is required to investigate how to better diagnose cows at risk 
for SCK at 3  weeks prepartum. In western Europe, cows “fat, 
old, and previously sick” (meaning with too high BCS compared 
to expected one, in parity 3 or higher, and with ketosis-related 
illness the previous lactation), are targeted for the use of the 
bolus. This should stay the present criteria of decision, wait-
ing for future more precise indicators to identify cows at risk. 
Considering this and the farmer’s expected ability to target 
SCK-at-risk animals, the good targeting situation (p  =  0.8, 
q =  0.2) proposed in the present work seems appropriate to 
represent the average situation in the field.
The present work did not consider the treatment of all cows in 
a herd since this is constitutes off-label monensin use in Europe. 
Preventative monensin bolus use in cows not at risk for SCK is 
a potential situation in the field that is linked to difficulties in 
correctly identifying cows at risk for SCK. However, this should 
not be interpreted as a suggestion to undertake extra-label 
monensin use.
The CSCK was estimated on average to be €257 per cow with 
SCK. Its sensitivity to the margin over feed cost was low. The CSCK 
was €244, €250, €257, €267, €276, and €289 for a margin over 
feed cost of €80, €100, €120, €150, €180, and €210 per ton of milk, 
respectively (7). Comparison of this abovementioned variability 
in CSCK for various margins over feed cost with changes in the 
TotalCostSCK for various CSCK (Figure  8) clearly shows that the 
conclusions of the present work are still valid for low or high 
market prices of milk. Furthermore, CSCK was included in the 
present model as a law of distribution. Thus, CSCK = N(257,94) 
accounted for a significant portion of the variation in the margin 
over feed cost usually faced in Europe.
Methods and Model calibration
The present work stressed a robust calibration, which is consist-
ent with similar studies (6, 7). First, given the 95% PI, it was 
difficult to predict the expected TotalCostSCK. The prediction 
remained correct for the prevalence of SCK (Figure 4) and was 
lower than for the TotalCostSCK due to the large 95% PI observed 
for CSCK (7). Despite the large 95% PI for the TotalCostSCK, the 
probability of achieving the average value reported in the graphs 
was high. Additionally, the PSCK values in the present work agree 
with the values observed in the field (3–5). Thus, the present 
model was correctly calibrated in accordance with the efforts 
made to accurately estimate the different input parameters, 
including a previous meta-analysis (2), a review of the param-
eters (7), and complementary work performed for this study 
(6). Moreover, the value of parameter d highly influenced the 
10
Raboisson and Barbier Profitability of Preventing SCK
Frontiers in Veterinary Science | www.frontiersin.org March 2017 | Volume 4 | Article 35
reFerences
1. Duffield TF, Lissemore KD, McBride BW, Leslie KE. Impact of hyperke-
tonemia in early lactation dairy cows on health and production. J Dairy 
Sci (2009) 92(2):571–80. doi:10.3168/jds.2008-1507 
2. Raboisson D, Mounie M, Maigne E. Diseases, reproductive performance, and 
changes in milk production associated with subclinical ketosis in dairy cows: 
a meta-analysis and review. J Dairy Sci (2014) 97(12):7547–63. doi:10.3168/
jds.2014-8237 
3. Philippe P, Raboisson D. Prévalence de la cétose subclinique dans les 
troupeaux bovins laitiers de l’Ouest de la France. Rencontres Recherche 
Ruminants (2012) 137. 
4. Vanholder T, Papen J, Bemers R, Vertenten G, Berge AC. Risk factors for 
subclinical and clinical ketosis and association with production param-
eters in dairy cows in the Netherlands. J Dairy Sci (2015) 98(2):880–8. 
doi:10.3168/jds.2014-8362 
5. Berge AC, Vertenten G. A field study to determine the prevalence, dairy 
herd management systems, and fresh cow clinical conditions associated with 
ketosis in western European dairy herds. J Dairy Sci (2014) 97(4):2145–54. 
doi:10.3168/jds.2013-7163 
6. Raboisson D, Barbier M, Maigne E. How metabolic diseases impact the 
use of antimicrobials: a formal demonstration in the field of veterinary 
medicine. PLoS One (2016) 11(10):e0164200. doi:10.1371/journal.pone. 
0164200 
7. Raboisson D, Mounie M, Khenifar E, Maigne E. The economic impact of 
subclinical ketosis at the farm level: tackling the challenge of over-esti-
mation due to multiple interactions. Prev Vet Med (2015) 122(4):417–25. 
doi:10.1016/j.prevetmed.2015.07.010 
8. Ospina PA, Nydam DV, Stokol T, Overton TR. Association between the 
proportion of sampled transition cows with increased nonesterified fatty 
acids and beta-hydroxybutyrate and disease incidence, pregnancy rate, 
and milk production at the herd level. J Dairy Sci (2010) 93(8):3595–601. 
doi:10.3168/jds.2010-3074 
9. Duffield TF, Sandals D, Leslie KE, Lissemore K, McBride BW, Lumsden JH, 
et al. Effect of prepartum administration of monensin in a controlled-release 
capsule on postpartum energy indicators in lactating dairy cows. J Dairy 
Sci (1998) 81(9):2354–61. doi:10.3168/jds.S0022-0302(98)70126-2 
10. Duffield TF, Sandals D, Leslie KE, Lissemore K, McBride BW, Lumsden 
JH, et al. Efficacy of monensin for the prevention of subclinical ketosis in 
lactating dairy cows. J Dairy Sci (1998) 81(11):2866–73. doi:10.3168/jds.
S0022-0302(98)75846-1 
11. Viechtbauer W. Conducting meta-analyses in R with the metafor package. 
J Stat Softw (2010) 36(3):1–48. doi:10.18637/jss.v036.i03 
12. Sauer FD, Kramer JK, Cantwell WJ. Antiketogenic effects of monensin 
in early lactation. J Dairy Sci (1989) 72(2):436–42. doi:10.3168/jds.
S0022-0302(89)79125-6 
13. Thomas EE, Poe SE, McGuffey RK, Mowrey DH, Alrich RD. Effect of feeding 
monensin to dairy cows on milk production and serum metabolite during 
early lactation. J Dairy Sci (1993) 76(Suppl 1):280. 
Conflict of Interest Statement: The authors’ institution received payment from 
Elanco France for other work. The present work has not been funded by Elanco.
Copyright © 2017 Raboisson and Barbier. This is an open-access article distrib-
uted under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in 
this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these 
terms.
model because the definitions of a, b, and c are dependent on 
d. However, the meaning and the validity of the results were 
not modified by changes in the value of d. The value of RRSCK 
IF AT RISK (2.0 or 4.5) remained imprecise. Factors such as feed 
access around calving or diet energy density after calving may 
impact the value of RRSCK IF AT RISK. Indeed, the results obtained 
with a RRSCK IF AT RISK = 2.0 or 4.5 may correspond to the farmer’s 
decision when fat cows are detected late in the dry period; 
possible decisions range from (i) no change in practice to (ii) 
improvements in dietary intake and the precise monitoring of 
cows identified to be at risk for SCK. Last, the present work 
focuses on a scenario in which c = d, i.e., no monensin bolus use 
on cows not at risk for SCK. As a reduction in the baseline risk 
for SCK cannot be excluded in cases of preventative monensin 
bolus treatment of cows not at risk for SCK, a related scenario 
was also proposed, and the results were very similar to the 
results obtained with c = d.
cOnclUsiOn
The present work highlights different economic strategies to 
manage SCK in the dairy industry in Europe, considering, 
among others, monensin bolus use. First, monensin bolus use 
when the SCK risk prevalence (r) is high is profitable but only in 
the short-term as a tool to correct an acute herd-level situation. 
Additionally, decreasing the SCK risk prevalence (r) is of finan-
cial interest as a baseline strategy when this prevalence is high. 
Finally, monensin bolus use when the SCK risk prevalence (r) 
is low is also profitable as a long-term strategy but only in cases 
where cows are precisely targeted according to their risk of SCK 
(by the farmer or other personnel). Further work is required to 
analyze the optimal prevalence of cows at risk for SCK in Europe 
considering the cost of decreasing this prevalence and also to 
investigate and define clear indicators to classify cows at risk for 
SCK as early as 3 weeks prepartum.
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